

<b>Coordinates (allele) Gene, amino acid</b>	<b>Associated trait</b>
chr1:25589952(C) <i>RHCE</i> , 226A	RH E/e polymorphism
<b>chr1:98121473(G) <i>DPYD</i>, 29R</b>	<b>Dihydropyrimidine dehydrogenase deficiency</b>
chr1:114179091(A) <i>PTPN22</i> , 620W	Diabetes mellitus, insulin-dependent, susceptibility to Hashimoto thyroiditis, susceptibility to, included; rheumatoid arthritis, susceptibility to, included; systemic lupus erythematosus, susceptibility to, included
chr1:154375026(G[A]) <i>LMNA</i> , 608G	<del>Hutchinson-Gilford progeria syndrome Restrictive dermopathy, lethal, included</del>
<b>chr1:155115542(C) <i>NTRK1</i>, 604H</b>	<b>Thyroid carcinoma, familial medullary</b>
<b>chr1:155115570(G) <i>NTRK1</i>, 613G</b>	<b>Thyroid carcinoma, familial medullary</b>
chr1:194908856(G) <i>CFH</i> , 62V	Macular degeneration, age-related, 4, susceptibility to
chr1:194925860(C) <i>CFH</i> , 402H	Macular degeneration, age-related, 4, susceptibility to Basal laminar drusen, included; myocardial infarction, susceptibility to, included
chr2:38151842(C[T]) <i>CYP11B1</i> , 387E[K]	<del>Glaucoma 3, primary congenital, A</del>
chr2:49043425(C) <i>FSHR</i> , 680S	Ovarian response to FSH stimulation Ovarian hyperstimulation syndrome, moderator of severity of, included
chr2:49044545(C) <i>FSHR</i> , 307A	Ovarian response to FSH stimulation
chr2:215943291(C) <i>FN1</i> , 1974R	Glomerulopathy with fibronectin deposits 2 [susceptibility to?]
chr3:115373505(C) <i>DRD3</i> , 9G	Schizophrenia, susceptibility to Essential tremor, susceptibility to, included
chr5:33987450(C) <i>SLC45A2</i> , 374L	Skin/hair/eye pigmentation 5, black/nonblack hair Skin/hair/eye pigmentation 5, dark/fair skin, included; skin/hair/eye pigmentation 5, dark/light eyes, included
<b>chr5:35896825(T) <i>IL7R</i>, 66I</b>	<b>Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive</b>
<b>chr5:35906947(G) <i>IL7R</i>, 138V</b>	<b>Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive</b>
<b>chr5:74017026(T) <i>HEXB</i>, 62L</b>	<b>Sandhoff disease, infantile type</b>
chr5:147461148(A) <i>SPINK5</i> , 420K	Atopy, susceptibility to Asthma, susceptibility to, included; dermatitis, atopic, 6, susceptibility to, included
chr5:148186633(G) <i>ADRB2</i> , 16G	Obesity, susceptibility to, included Asthma, nocturnal, susceptibility to

<b>Coordinates (allele) Gene, amino acid</b>	<b>Associated trait</b>
chr5:148186666(G) <i>ADRB2, 27E</i>	Obesity, susceptibility to Asthma, childhood, susceptibility to, included
chr6:32904663(A) <i>TAP2, 687*</i>	Peptide transporter PSF2 polymorphism
chr6:32904729(T) <i>TAP2, 665T</i>	Peptide transporter PSF2 polymorphism
chr6:32908390(C) <i>TAP2, 379V</i>	Peptide transporter PSF2 polymorphism
chr6:38758606(T) <i>GLO1, 111E</i>	Autism, susceptibility to
chr6:46780902(A) <i>PLA2G7, 379V</i>	Asthma and atopy, susceptibility to
<b>chr6:112489016(C) <i>WISP3, 78R</i></b>	<b>Arthropathy, progressive pseudorheumatoid, of childhood</b>
chr6:149763383(G) <i>SUMO4, 55V</i>	Diabetes mellitus, insulin-dependent, 5 [susceptibility to]
chr6:160033862(A) <i>SOD2, 16V</i>	Superoxide dismutase 2 polymorphism
chr7:94872711(G) <i>PON2, 311S</i>	Paraoxonase 2 polymorphism
chr7:116986769(G) <i>CFTR, 470V</i>	CFTR polymorphism
chr7:122422409(A) <i>TAS2R16, 172N</i>	Alcohol dependence
chr7:141319174(G) <i>TAS2R38, 262A</i>	Phenylthiocarbamide tasting
chr7:150327044(T) <i>NOS3, 298D</i>	Coronary spasm, susceptibility to Alzheimer disease, late-onset, susceptibility to, included; hypertension, pregnancy-induced, susceptibility to, included; hypertension, resistant to conventional therapy, included; ischemic heart disease, susceptibility to, included; ischemic stroke, susceptibility to, included
<b>chr9:135304807(G) <i>ADAMTS13, 951G</i></b>	<b>Thrombotic thrombocytopenic purpura, congenital</b>
chr10:64085190(A) <i>ZNF365, 62T</i>	Uric acid nephrolithiasis, susceptibility to
chr10:75343107(T) <i>PLAU, 141L</i>	Alzheimer disease, late-onset, susceptibility to
chr10:115795046(G) <i>ADRB1, 389G</i>	Beta-1-adrenergic receptor polymorphism, gain-of-function Congestive heart failure, susceptibility to
chr10:115795047(G) <i>ADRB1, 389G</i>	Beta-1-adrenergic receptor polymorphism, gain-of-function Congestive heart failure, susceptibility to

<b>Coordinates (allele) Gene, amino acid</b>	<b>Associated trait</b>
chr11:5203410(A) <i>HBB</i> , 146Y	Hemoglobin Bologna-St. Orsola
chr11:5203412(A) <i>HBB</i> , 146Y	Hemoglobin Bologna-St. Orsola
chr11:5203453(T) <i>HBB</i> , 132Q	Hemoglobin K (Woolwich)
chr11:5203454(G) <i>HBB</i> , 132Q	Hemoglobin K (Woolwich)
chr11:5203485(T) <i>HBB</i> , 121K	Hemoglobin Egypt Hemoglobin O (Arab)
chr11:5203486(T) <i>HBB</i> , 121K	Hemoglobin Egypt Hemoglobin O (Arab)
chr11:5203487(T) <i>HBB</i> , 121K	Hemoglobin Egypt Hemoglobin O (Arab)
chr11:5204402(A) <i>HBB</i> , 99V	Hemoglobin Chemilly
chr11:5204408(A) <i>HBB</i> , 97L	Hemoglobin Wood
chr11:5204409(G) <i>HBB</i> , 97L	Hemoglobin Wood
chr11:5204415(C) <i>HBB</i> , 95D	Hemoglobin N, beta type
chr11:5204478(C) <i>HBB</i> , 74D	Hemoglobin Shepherds Bush
chr11:5204558(C) <i>HBB</i> , 47G	Hemoglobin Gavello
chr11:5204559(C) <i>HBB</i> , 47G	Hemoglobin Gavello
chr11:5204564(G) <i>HBB</i> , 45S	Hemoglobin Cheverly
chr11:5204605(C) <i>HBB</i> , 31R	Hemoglobin Hakkari
chr11:5204736(C) <i>HBB</i> , 31R	Hemoglobin Hakkari
chr11:5204737(T) <i>HBB</i> , 31R	Hemoglobin Hakkari
chr11:5204751(C) <i>HBB</i> , 26G	Hb Aubenas
chr11:5204752(C) <i>HBB</i> , 26G	Hb Aubenas

<b>Coordinates (allele) Gene, amino acid</b>	<b>Associated trait</b>
chr11:5204757(A) <i>HBB, 24V</i>	Hemoglobin Savannah
chr11:5204758(C) <i>HBB, 24V</i>	Hemoglobin Savannah
chr11:5204805(T) <i>HBB, 8E</i>	Hemoglobin N (Timone)
chr11:5231166(T) <i>HBG2, 121K</i>	Hemoglobin F (Carlton)
chr11:17366148(T) <i>KCNJ11, 23K</i>	Diabetes mellitus, noninsulin-dependent, susceptibility to
<b>chr11:17487669(G) <i>USH1C, 608P</i></b>	<b>Deafness, neurosensory, autosomal recessive 18</b>
chr11:66084671(T) <i>ACTN3, 577*</i>	Actinin, alpha-3 polymorphism ACTN3 deficiency; sprinting performance
chr12:9123535(T) <i>A2M, 1000I</i>	Alpha-2-macroglobulin polymorphism Alzheimer disease, susceptibility to, included
chr12:14884706(C) <i>ART4, 265D</i>	Dombrock blood group
chr12:110368991(T) <i>SH2B3, 262W</i>	Diabetes mellitus, insulin-dependent, susceptibility to Celiac disease, susceptibility to, 13, included
chr12:111833253(G) <i>OAS1, 162G</i>	Diabetes mellitus, type 1, susceptibility to
chr12:119921765(A) <i>HNF1A, 574S</i>	Hepatic adenoma [susceptibility to?]
<b>chr12:120779718(T) <i>HPD, 33T</i></b>	<b>Hawkinsinuria</b>
chr14:20010446(G) <i>NP, 51G</i>	Nucleoside phosphorylase polymorphism
chr15:46213776(A) <i>SLC24A5, 111T</i>	Skin/hair/eye pigmentation 4, fair/dark skin
chr16:167318(C) <i>HBA1, 113H</i>	Hemoglobin Twin Peaks
chr16:167319(A) <i>HBA1, 113H</i>	Hemoglobin Twin Peaks
chr16:167322(T) <i>HBA1, 114L</i>	Hemoglobin Nouakchott
chr16:167328(C) <i>HBA1, 116A</i>	Hemoglobin Ube-4
chr16:3647748(G) <i>DNASE1, 244R</i>	Systemic lupus erythematosus, susceptibility to

<b>Coordinates (allele) Gene, amino acid</b>	<b>Associated trait</b>
<b>chr16:55106002(C) BBS2, 70S</b>	<b>Bardet-Biedl syndrome 2</b>
chr16:87240737(A) CYBA, 72Y	CYBA polymorphism 242C-T
chr17:35133111(A) ERBB2, 654I	ERBB2 polymorphism
chr17:35133114(A) ERBB2, 655I	ERBB2 polymorphism
chr18:9107867(T) NDUFV2, 29V	Parkinson disease, susceptibility to
chr19:6664262(G) C3, 314P	C3 polymorphism, HAV 4-1 plus/minus type
chr21:33536120(T) IFNAR2, 8F	Hepatitis B virus, susceptibility to
chr21:33562658(A) IL10RB, 47K	Hepatitis B virus, susceptibility to
chr22:17281004(C) PRODH, 521R	Hyperprolinemia, type I Schizophrenia, susceptibility to, 4, included
chr22:29341610(G) TCN2, 259R	TCN2 polymorphism